NCT01279798No Longer Available不适用
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03. A total of 45 patients will be enrolled into the study.
详细描述
The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.
The secondary objectives of this study are:
- Evaluate the best overall tumor response.
- Evaluate progression-free survival (PFS).
- Evaluate treatment toxicity.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •≥ 18 years
- •Histological confirmed non-curable stage III or IV NSCLC.
- •Must have completed at least one (1) regimen of anti-cancer therapy.
- •Following frontline therapy, subjects must observe the following wash- out periods:
- •Subjects with stable disease or better must have received the last anti-cancer therapy not less than five months prior to enrollment.
- •Subjects with progressive disease must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
- •All subjects who have received two (2) or more regimens of therapy must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
- •Performance status (ECOG) ≤ 2
- •Absolute granulocyte count ≥ 1,500/mm3
- •Platelet count ≥ 100,000/mm3
- •Total Bilirubin ≤ 2× Upper Limit of Normal
- •AST and ALT ≤ 2× Upper Limit of Normal
- •Creatinine ≤ 2× Upper Limit of Normal
- •Negative pregnancy test for women of childbearing potential.
排除标准
- •Concurrent systemic steroids > 2 mg prednisone/day
- •Prior splenectomy
- •Any chemotherapy, steroid therapy, or investigational anti-cancer agent within 4 weeks of study entry.
- •Subjects who received prior monotherapy with Lucanix.
- •Symptomatic brain metastases unless treated and stable for ≥ 2 months
- •Known HIV positivity
- •Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.
- •Prior malignancy (excluding non-melanoma carcinomas of the skin) unless in remission for ≥ 2 years
- •History of psychiatric disorder that would impede adherence to protocol
- •Pregnant or nursing women or refusal to practice contraception if of reproductive potential
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Primary HyperoxaluriaNCT04125472Alnylam Pharmaceuticals
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.
No Longer Available
不适用
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNon-Small Cell Lung CancerNCT02271139Genentech, Inc.
Available
不适用
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNCT04457687Eisai Inc.
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell LymphomaNCT05776134Kite, A Gilead Company